

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
NIH142.001C1APPLICATION NO.
09/610,034INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEPARATE SHEETS IF NECESSARY)

APPLICANT
Gu, et al.FILING DATE
July 5, 2000GROUP
1645Examiner
Int.

NOV 16 2000

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
KSS	1	5,556,755	09/17/96	Murphy	435	6	9/29/1993
KSS	2	5,607,846	03/04/97	Murphy, et al.	435	69.3	3/4/1997
KSS	3	5,334,379	08/02/94	Pillai, et al.	424	85.2	8/2/1994

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
KSS	4	98/53851	12/03/98	WO/98/01001 WIPO	A61K	39/02	✓	

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
KSS	5	Ahmed, K., et al. (1991) Possible presence of a capsule in <i>Branhamella catarrhalis</i> . Microbiol. Immunol. 35: 361-366
	6	Alaeus, A., et al. (1991) <i>Branhamella catarrhalis</i> septicemia in an immunocompetent adult. Scand. J. Infect. Dis. 23: 115-116
KSS	7	Barenkamp, S.J. (1996) Immunization with high-molecular-weight adhesion proteins of nontypeable <i>Haemophilus influenzae</i> modifies experimental otitis media in chinchillas. Infect. Immun. 64: 1246-1251
KSS	8	Bhushan, R., et al. (1994) Molecular cloning and characterization of outer membrane protein E of <i>Moraxella (Branhamella) catarrhalis</i> . J. Bacteriol. 176: 6636-6643
KSS	9	Blueston, C.D. (1986) Otitis media and sinusitis in children. Role of <i>Branhamella catarrhalis</i> . Drugs 31 (Suppl. 3): 132-141

EXAMINER	<i>Kushal Sin</i>	DATE CONSIDERED	7/28/01
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			


FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. NIH142.001C1	APPLICATION NO. 09/610,034
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Gu, et al.	
		FILING DATE July 5, 2000	GROUP 1645

 Examiner
Int.

KSS	10	Boyle, F.M., et al., (1991) <i>Branhamella</i> (Moraxella) catarrhalis: pathogenic significance in respiratory infections. Med. J. Aust. 154:592-596
KSS	11	Campagnari, A., et al., (1994) Growth of <i>Moraxella catarrhalis</i> with human transferrin and lactoferrin: expression of iron-repressible proteins without siderophore production. Infect. Immun. 62:4909-4914
KSS	12	Catlin, B.W. (1990) <i>Branhamella catarrhalis</i> : an organism gaining respect as a pathogen. Clin. Microbiol. Rev. 3:293-320
KSS	13	Chapman, A.J., Jr., et al. (1985) Development of bactericidal antibody during <i>Branhamella catarrhalis</i> infection. J. Infect. Dis. 151:878-882
KSS	14	Chen, D., et al., (1996) Evaluation of purified UspA from <i>Moraxella catarrhalis</i> as a vaccine in a murine model after active immunization. Infect. Immun. 64:1900-1905.
KSS	15	Christensen, J.J., et al., (1996) Serum antibody response to outer membrane proteins of <i>Moraxella</i> (<i>Branhamella</i>) <i>catarrhalis</i> in patients with bronchopulmonary infection. Clin. diagn. Lab. Immunol. 3:717-721
KSS	16	Cohen, D., et al. (1997) Double-blind vaccine-controlled randomised efficacy trial of an investigational <i>Shigella sonnei</i> conjugate vaccine in young adults. Lancet 340:155-159
KSS	17	Doern, G.V. (1986) <i>Branhamella catarrhalis</i> - an emerging human pathogen. Diagn. Microbiol. Infect. Dis. 4: 191-201
KSS	18	Doyle, W.J. (1989) Animal models of otitis media: other pathogens. Pediatr. Infect. Dis J. 8:Suppl. 45-47
KSS	19	Edebrink, P., et al. (1994) Structural studies of the O-polysaccharide from the lipopolysaccharide of <i>Moraxella</i> (<i>Branhamella</i>) <i>catarrhalis</i> serotype A (strain ATCC 25238). Carbohydr. Res. 257:269-284
KSS	20	Edebrink, P., et al. (1995) Structural studies of the O-antigen oligosaccharides from two strains of <i>Moraxella catarrhalis</i> serotype C. Carbohydr. Res. 266:237-261
KSS	21	Edebrink, P., et al. (1996) The structures of oligosaccharides isolated from the lipopolysaccharide of <i>Moraxella catarrhalis</i> serotype B, strain CCUG 3292. Carbohydr. Res. 295: 127-146
KSS	22	Ejlersten, T., et al. (1994) <i>Branhamella catarrhalis</i> in children and adults. A study of prevalence, time of colonisation, and association with upper and lower respiratory tract infections. J. Infect. 29:23-31
KSS	23	Eliasson, I. (1986) Serological identification of <i>Branhamella catarrhalis</i> . Serological evidence for infection. Drugs 31(Suppl. 3):7-10
KSS	24	Enright, M.C., et al. (1997) <i>Moraxella</i> (<i>Branhamella</i>) <i>catarrhalis</i> -clinical and molecular aspects of a rediscovered pathogen. J. Med. Micro-biol. 46:360-371.
KSS	25	Faden, H., et al. (1994) Epidemiology of <i>Moraxella catarrhalis</i> in children during the first 2 years of life: relationship to otitis media. J. Infect. Dis. 169:1312-1317
KSS	26	Fomsgaard, J. S., et al. (1991) Comparative immunochemistry of lipopolysaccharides from <i>Branhamella catarrhalis</i> strains. Infect. Immun. 59:3346-3349
KSS	27	Fung, C.P., et al. (1992) The antimicrobial susceptibility of <i>Moraxella catarrhalis</i> isolated in England and Scotland in 1991. J. Antimicrob. Chemother. 30:47-55
KSS	28	Goldblatt, D., et al. (1990) <i>Branhamella catarrhalis</i> : antigenic determinants and the development of the IgG subclass response in childhood. J. Infect. Dis. 162:1128-1135
KSS	29	Green, B.A., et al. (1994) Nontype <i>Haemophilus influenzae</i> Lipo-oligosaccharide Conjugates as Vaccine Candidates against NTHi, p. 125-129. In E. Norby, F. Brown, R.M. Chanock, and H.S. Ginsberg (ed), Vaccines 94. Cold Spring Harbor Laboratory Press, Plainview, N.Y.
KSS	30	Gu, X.-X., et al. (1997) Detoxified lipooligosaccharide from nontypeable <i>Haemophilus influenzae</i> conjugated to proteins confers protection against otitis media in chinchillas. Infect. Immun. 65:4488-4493
KSS	31	Gu, X.-X., et al. (1993) Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugates. Infect. Immun. 61:1873-1880
KSS	32	Gu, X.-X., et al. (1998) Synthesis and Characterization of Lipooligosaccharide-Based Conjugates as Vaccine Candidates for <i>Moraxella</i> (<i>Branhamella</i>) <i>catarrhalis</i> . Infect. Immun. 66:1891-1897
KSS	33	Gu, X.-X., et al. (1995) Quantitation and biological properties of released and cell-bound lipooligosaccharides from nontypeable <i>Haemophilus influenzae</i> . Infect. Immun. 63:4115-4120.
KSS	34	Gu, X.-X., et al. (1996) Synthesis, characterization, and immunological properties of detoxified lipooligosaccharide from nontypeable <i>Haemophilus influenzae</i> conjugated to proteins. Infect. Immun. 64:4047-4053.
KSS	35	Gupta, R.K., et al. (1992) Synthesis, characterization, and immunological properties of conjugates composed of the detoxified lipopolysaccharide of <i>Vibrio cholerae</i> O1 serotype Inaba bound to cholera toxin. Infect. Immun. 60:3201-3208

EXAMINER	<i>Kent Johnson</i>	DATE CONSIDERED	2/28/01
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. NIH142.001C1	APPLICATION NO. 09/610,034
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Gu, et al.	
		FILING DATE July 5, 2000	GROUP 1645



	Helminen, M.E., et al. (1993) A major outer membrane protein of <i>Moraxella catarrhalis</i> is a target for antibodies that enhance pulmonary clearance of the pathogen in an animal model. <i>Infect. Immun.</i> 61:2003-2010
KSS	37 Helminen, M.E., et al. (1994) A large, antigenically conserved protein on the surface of <i>Moraxella catarrhalis</i> is a target for protective antibodies. <i>J. Infect. Dis.</i> 170:867-872
KSS	38 Hochstein, H.D., et al. (1973) Further developments of Limulus amebocyte lysate test. <i>Bull. Paraenter. Drug Assoc.</i> 27:139-148
KSS	39 Hu, W.-G., et al. (2000) Enhancement of Clearance of Bacteria from Murine Lungs by Immunization with Detoxified Lipooligosaccharide from <i>Moraxella catarrhalis</i> Conjugated to Proteins. <i>Infect. Immun.</i> 68:4980-4985
KSS	40 Jennings, H.J., et al. (1984) Conjugation of meningococcal Lipopolysaccharide R-type oligosaccharides to tetanus toxoid as route to a potential vaccine against group B <i>Neisseria meningitidis</i> . <i>Infect. Immun.</i> 43:407-412
KSS	41 Kelly, J., et al. (1996) Separation and Characterization of O-Deacylated Lipooligosaccharides and Glycans Derived from <i>Moraxella catarrhalis</i> Using Capillary Electrophoresis-electrospray Mass Spectrometry and Tandem Mass Spectrometry. <i>Analy. Biochem.</i> 233:15-30
KSS	42 Kemp, H.A., et al. (1986) Studies on the detrimental effects of bivalent binding in a microtiter plate ELISA and possible remedies. <i>J. Immunol. Methods</i> 94:65-72
KSS	43 Marrs, C.F., et al. (1990) Pili (fimbriae) of <i>Branhamella</i> species. <i>Am.J.Med.</i> 88(Suppl. 5A):36S-40S
KSS	44 Masoud, H., et al. (1994) Structural elucidation of the backbone oligosaccharide for the lipopolysaccharide of <i>Moraxella catarrhalis</i> serotype A. <i>Can. J. Chem.</i> 72:1466-1477
KSS	45 Masoud, H., et al. (1994) Characterization of the lipopolysaccharide of <i>Moraxella catarrhalis</i> . Structural analysis of the lipid A from M. catarrhalis serotype A lipopolysaccharide. <i>Eur.J. Biochem.</i> 220:209-216
KSS	46 McLeod, D.T., et al., (1986) Increase in bronchopulmonary infection due to <i>Branhamella catarrhalis</i> . <i>Br. Med. J.</i> 292:1103-1105
KSS	47 Murphy, T.F. (1996) <i>Branhamella catarrhalis</i> : epidemiology, surface antigenic structure, and immune response. <i>Microbiol. Rev.</i> 60:267-279
KSS	48 Murphy, T.F., et al. (1993) The major heat-modifiable outer membrane protein CD is highly conserved among strains of <i>Branhamella catarrhalis</i> . <i>Mol. Microbiol.</i> 10:87-97
KSS	49 Nicotra, B., et al. (1986) <i>Branhamella catarrhalis</i> as a lower respiratory tract pathogen in patients with chronic lung disease. <i>Arch. Intern. Med.</i> 146:890-893
KSS	50 Rahman, M., et al. (1995) Lack of serotype-specific antibody response to lipopolysaccharide antigens of <i>Moraxella catarrhalis</i> during lower respiratory tract infection. <i>Eur. J. Clin. Microbiol. Infect. Dis.</i> 14:297-304
KSS	51 Rahman, M., et al. (1997) Human immunoglobulin isotype and IgG subclass response to different antigens of <i>Moraxella catarrhalis</i> . <i>APMIS</i> 105:213-220
KSS	52 Robbins, J.B., et al. (1990) Polysaccharide-protein conjugates: a new generation of vaccines. <i>J.Infect. Dis.</i> 161:821-832
KSS	53 Robbins, J.B., et al. (1995) Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. <i>J.Infect. Dis.</i> 171:1387-1398
KSS	54 Sarubbi, F.A., et al. (1990) Respiratory infections caused by <i>Branhamella catarrhalis</i> . Selected epidemiologic features. <i>Am. J. Med.</i> 88 Suppl 5A:9S-14S
KSS	55 Smith, P.K., et al. (1985) Measurement of protein using bicinchoninic acid. <i>Anal. Biochem.</i> 150:76-85
KSS	56 Svenson, S.B., et al. (1981) Artificial <i>Salmonella</i> vaccines: <i>Salmonella typhimurium</i> O-antigen-specific oligosaccharide-protein conjugates elicit protective antibodies in rabbits and mice. <i>Infect.Immun.</i> 32:490-496
KSS	57 Tsai, C.M., et al. (1982) A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. <i>Anal Biochem.</i> 119:155-119
KSS	58 Vaneechoutee, M., et al. (1990) Respiratory tract carrier rates of <i>Moraxella (Branhamella) catarrhalis</i> in adults and children and interpretation of the isolation of M. catarrhalis from sputum. <i>J. Clin. Microbiol.</i> 28:2674-2680
KSS	59 Vaneechoutee, M., et al. (1990) Serological Typing of <i>Branhamella catarrhalis</i> strains on the basis of lipopolysaccharide antigens. <i>J. Clin. Microbiol.</i> 28:182-187
KSS	60 Verheul, A.F.M., et al. (1991) Preparation, characterization, and immunogenicity of meningococcal immunotype L2 and L3,7,9, phosphoethanolamide group-containing oligosaccharide-protein conjugates. <i>Infect.Immun.</i> 59:843-851
KSS	61 Wagner, D.K., et al. (1987) Analysis of immunoglobulin G antibody responses after administration of live and inactively influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum. <i>J. Clin. Microbiol.</i> 25:559-562
KSS	62 W.H.O. Expert Committee on Biological Standardization (1991) Requirements for <i>Haemophilus</i> type b conjugate vaccines. <i>WHO Tech. Rep. Ser.</i> 814:15-37

EXAMINER	<i>K. K. K.</i>	DATE CONSIDERED	7/28/01
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. NIH142.001C1		APPLICATION NO. 09/610,034	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)				APPLICANT Gu, et al.			
				FILING DATE July 5, 2000		GROUP 1645	
Examiner 63 Lang, Y.P., et al. (1997) The major outer membrane protein, CD, extracted from <i>Moraxella (Branhamella) catarrhalis</i> is a potential vaccine antigen that induces bactericidal antibodies. FEMS Immunol. Med. Microbiol. 17:187-199							
64 Zollinger, W.D., et al. (1983) Importance of complement source in bactericidal activity of human and murine monoclonal antibody to meningococcal group B polysaccharide. Infect. Immun. 40:257-264							

O:\DOCS\KRM\KRM-1038.DOC
110600

EXAMINER <i>Kerubon</i>	DATE CONSIDERED <i>7/28/01</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	